Fervent Clinical Results Promising for Menopause Symptom Relief

Fervent logo

Fervent Pharmaceuticals, a clinical-stage drug development company based in Greenville, has announced positive results from its Phase 2A clinical trial of FP-101, a non-hormonal, non-herbal, non-antidepressant treatment of the vasomotor symptoms that accompany menopause.

“We’re pleased to receive these results, which help us move even closer to providing a safe and effective solution for women who suffer from hot flashes and night sweats during menopause,” said George Royster, founder and CEO of Fervent. “We are also pleased that FP-101 demonstrates the potential to bring relief to breast cancer survivors coping with hot flashes and night sweats caused by their ongoing cancer treatments.”

The eight-week placebo-controlled study indicated that the patients experienced a reduction in their hot flashes and night sweats versus placebo. 

The clinical trial included a six patient sub-study of breast cancer survivors undergoing Tamoxifen treatment. Tamoxifen is often prescribed to breast cancer survivors but the drug can cause a side effect of inducing hot flashes and night sweats. FP-101 helped minimize these side effects. FP-101 is a repurposed drug and its active ingredient has a long history of safe use.

“We anticipate FP-101 will be an important option for women’s healthcare,” said Ernest Mario, Ph.D., a Fervent board member and former North Carolina Biotechnology Center board member. “These early results are quite encouraging.”

This is encouraging news for breast cancer survivors taking Tamoxifen who can’t take treatments options such as hormone replacement therapy or antidepressants due to cancer risk or drug-drug interactions.

Wyatt Corbett, NCBiotech Writer
scroll back to top of page